SecBot SecBot

ADIL

ADIAL PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001513525 Biotech & Drug Discovery
$3.92 −0.30 (−7.11%)
Oct 23 4:00 PM ET · prev $4.22
Market cap
$11.1M
Nano cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−56.4%
from $9.00 · Oct 24
30 days
−11.7%
from $4.44
52-week range
$1.36–9.50
−59% from high · low May 14
Avg volume 20D
35.3K
Oct 12 spike 167.0K
Short interest
183.3K
≈7.0% of shares · −12.7%
Days to cover
4.3
at average volume
Insider net
+$206.3K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 11 reports · 90 days
Balance 4 bearish · 3 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 10/11 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Adial Pharmaceuticals filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2026, primarily…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $206.3K at an average $2.70. No open-market sales. Price is 45% above their cost.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −12.7% to 183.3K shares. 4.3 days to cover, ≈7.0% of shares.

  • TrendDOWNTREND

    18% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED19,147$49.0K
GEODE CAPITAL MANAGEMENT, LLCTRIM12,393$31.7K
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED5,831$14.9K
BlackRock, Inc.TRIM304$778.00
JANE STREET GROUP, LLCDOUBLED121,841$26.8K
UBS Group AGTRIM9,167$2.0K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED164,127$58.0K
VANGUARD GROUP INCDOUBLED156,024$55.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy2Buy6Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 3, 2026Alliance Global Partners
INITIATE
INITIATEBuy
Jun 15, 2026LUCID CAPITAL MARKETS
INITIATE
INITIATEBuy

Insider ledger

Form 4
$206.3K
bought · 2 insiders
$0
sold · 0 insiders
+45.1%
vs their $2.70 cost
DateInsiderTypeValue
Sep 17, 2026
Young Wendy B.
Director
AWARD25,666 sh
Jul 16, 2026
Coastlands Capital LP
10%+ Owner
BUY$3.4K
Jul 14, 2026
Coastlands Capital LP
10%+ Owner
BUY$5.3K
Jul 10, 2026
Coastlands Capital LP
10%+ Owner
BUY$4.6K
Jul 9, 2026
Coastlands Capital LP
10%+ Owner
BUY$28.0K
Jun 29, 2026
Coastlands Capital LP
10%+ Owner
BUY$65.0K
Jun 12, 2026
Young Wendy B.
Director
BUY$100.0K
Jun 12, 2026
Davidson Matt
Chief Development Officer
AWARD232,417 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
183,323
shares short
-12.7%
vs prior settlement
4.3
days to cover
≈7.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Adial Pharmaceuticals filed Amendment No. 1 to its Form 10-Q for the quarter ended June 30, 2026, primarily to respond…
10-Q/A — Impact 7/10
Oct 20, 2026 SEC
Adial Pharmaceuticals filed Amendment No. 1 to its S-3 registration statement to register up to 25,148,970 shares of…
S-3/A — Impact 7/10
Oct 16, 2026 SEC
Adial Pharmaceuticals filed a DEFA14A to announce a further adjournment of its 2026 Annual Meeting for Proposals 3, 4…
DEFA14A — Impact 5/10
Sep 30, 2026 Press
Adial Pharmaceuticals granted a new employee stock option to purchase 155,446 shares at $4.22 as an inducement for…
Impact 2/10
Sep 30, 2026 FDA
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adi
Sep 17, 2026 Insider
Young Wendy B. was granted 25,666 shares
Director
Jul 16, 2026 Insider
Coastlands Capital LP bought 1,233 shares
10%+ Owner @ $2.75 ($3.4K)
Jul 14, 2026 Insider
Coastlands Capital LP bought 2,000 shares
10%+ Owner @ $2.65 ($5.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Sep 30, 2026
FDA
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GLEN ALLEN, Va., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the…
Aug 26, 2026
Listing
Listing Status: ADIL — Deficient (was Normal)
Adial Pharmaceuticals, Inc - Common Stock | Nasdaq Financial Status Indicator N → D
Aug 21, 2026
Reg SHO list
Reg SHO Threshold: ADIL exited the threshold list
ADIAL PHARMACEUTICALS INC COM | On list since 2026-08-04
Aug 17, 2026
Earnings
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in…
Aug 11, 2026
Earnings date
ADIL Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

13 filings · 4 press releases · 3 bullish · 5 bearish · 5 neutral
All ADIL filing & press-release reports (17)